Filing Details

Accession Number:
0001179110-18-010637
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-08-16 19:08:03
Reporting Period:
2018-08-14
Accepted Time:
2018-08-16 19:08:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1583107 Theravance Biopharma Inc. TBPH Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1607737 D Renee Gala C/o Theravance Biopharma Us, Inc.
901 Gateway Blvd
South San Francisco CA 94080
Svp, Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2018-08-14 2,204 $27.74 212,588 No 4 S Direct
Ordinary Shares Disposition 2018-08-15 39,839 $26.71 172,749 No 4 S Direct
Ordinary Shares Disposition 2018-08-15 1,700 $27.43 171,049 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. This transaction was executed in multiple trades at prices from $27.515 to $28.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
  2. This transaction was executed in multiple trades at prices from $26.265 to $27.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices from $27.27 to $27.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.